Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026- GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2026:
-
65,000 shares
-
€973,620.20
During the first half of 2026, total trading was:
-
On the buy side: 1,598,594 shares for a total amount of €12,813,126.30
-
On the sell side: 1,549,771 shares for a total amount of €12,677,508.21
During this same period, the number of trades were:
-
On the buy side: 3,200
-
On the sell side: 2,721
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:
-
27,911 shares
-
€769,849.43
END
ABOUT GENFIT
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding its research and development programs. The use of certain words, such as "believe", "potential", "expect", "target", "may", "will", "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACTS
GENFIT| Investors
Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com
GENFIT| Media
Bruno ARABIAN – Agence Maarc | Tel: 06 87 88 47 26 | bruno.arabian@maarc.fr
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
GENFIT| 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com
APPENDIX
H1 2026
Buy side
Sell-side
Date
Number of executions
Number of shares
Traded amounts in EUR
Number of executions
Number of shares
Traded amounts in EUR
TOTAL
3 200
1 598 594
12 813 126,30
2 721
1 549 771
12 677 508,21
02/01/2026
40
23001
121 230,22
37
20343
107 679,57
05/01/2026
47
23176
119 431,26
28
12011
62 387,18
06/01/2026
1
1
5,16
16
7001
36 885,19
07/01/2026
21
17001
91 071,98
6
5001
27 580,41
08/01/2026
21
12858
67 922,90
4
858
4 483,16
09/01/2026
19
11001
58 085,17
18
11001
58 185,17
12/01/2026
28
14411
75 680,66
12
8118
42 907,20
13/01/2026
20
9330
48 857,66
20
9330
49 159,12
14/01/2026
7
5276
27 949,77
21
16569
88 827,90
15/01/2026
13
9098
49 201,53
14
7760
42 426,64
16/01/2026
24
9154
48 508,60
8
3492
18 417,79
19/01/2026
21
13001
67 455,17
25
9464
49 632,06
20/01/2026
28
16464
85 027,50
22
11001
56 805,20
21/01/2026
14
8001
40 975,20
17
11001
57 360,20
22/01/2026
15
11001
59 055,24
25
16001
86 454,20
23/01/2026
15
16011
88 481,11
16
10511
58 200,67
26/01/2026
25
14055
77 320,91
3
555
3 094,13
27/01/2026
18
5893
32 583,87
20
12893
71 491,69
28/01/2026
19
9685
54 619,53
34
14749
83 721,08
29/01/2026
15
8657
48 872,31
10
24593
139 052,27
30/01/2026
12
10000
56 410,00
13
7866
44 521,56
02/02/2026
17
7001
38 870,60
23
15135
85 648,97
03/02/2026
14
5132
31 188,29
29
15132
92 903,37
04/02/2026
22
10252
63 414,77
17
9252
57 898,65
05/02/2026
33
15001
94 081,17
24
13219
83 049,56
06/02/2026
41
19810
121 962,84
13
7002
43 432,71
09/02/2026
17
12450
76 738,31
30
19040
118 363,68
10/02/2026
16
7001
45 474,02
33
15001
97 038,92
11/02/2026
16
10403
68 835,82
27
14403
95 687,91
12/02/2026
24
15001
105 536,84
22
13001
92 381,73
13/02/2026
26
24001
168 262,13
31
18001
127 784,06
16/02/2026
11
11001
81 340,95
28
16001
117 972,33
17/02/2026
20
8751
69 255,15
19
8751
68 320,11
18/02/2026
19
8501
67 105,53
11
3501
27 958,04
19/02/2026
38
11503
89 218,65
34
14253
114 044,24
20/02/2026
46
22930
179 214,92
2
180
1 422,13
23/02/2026
1
1
8,19
38
20001
168 318,22
24/02/2026
40
17551
158 835,50
44
22551
205 596,79
25/02/2026
21
10001
89 761,68
18
5001
45 839,22
26/02/2026
49
22001
195 236,65
5
2001
18 409,06
27/02/2026
28
13001
119 358,93
41
13501
125 618,84
02/03/2026
52
20251
169 647,49
16
14751
128 083,52
03/03/2026
54
19001
162 346,25
19
9001
77 041,18
04/03/2026
23
7001
59 184,28
35
19501
168 798,12
05/03/2026
17
8501
75 136,34
19
13501
121 718,81
06/03/2026
21
12251
105 158,79
5
2251
19 478,80
09/03/2026
12
4001
34 237,08
25
21501
186 434,53
10/03/2026
16
10081
94 559,88
27
15081
143 252,91
11/03/2026
28
20201
184 760,16
12
6201
57 500,38
12/03/2026
37
17761
157 053,60
7
5261
47 500,67
13/03/2026
29
13501
115 709,92
13
15001
130 096,17
16/03/2026
12
6751
57 260,90
12
15751
135 593,43
17/03/2026
16
10001
87 693,77
19
13001
114 658,81
18/03/2026
14
11751
103 861,33
28
11001
98 820,77
19/03/2026
9
5751
50 347,53
33
27001
242 970,12
20/03/2026
35
24001
212 785,43
6
5501
50 535,38
23/03/2026
20
9251
79 950,66
20
24251
213 809,91
24/03/2026
40
30001
259 904,06
8
5001
45 054,06
25/03/2026
13
7001
59 283,63
8
5001
42 938,64
26/03/2026
36
16212
136 949,57
19
11487
97 593,67
27/03/2026
35
20076
167 456,33
33
20076
167 871,30
30/03/2026
42
12419
102 356,65
16
13321
110 390,59
31/03/2026
12
10128
84 572,34
22
15951
134 857,09
01/04/2026
12
6751
58 381,16
27
11501
100 017,41
02/04/2026
37
15251
129 017,36
11
17251
147 546,08
07/04/2026
142
81006
638 469,04
1
1
8,58
08/04/2026
43
22914
180 072,65
38
25169
201 030,09
09/04/2026
14
14001
110 385,42
20
42001
332 987,71
10/04/2026
1
1
8,02
64
59251
498 113,08
13/04/2026
19
7501
64 912,00
17
8251
73 140,99
14/04/2026
20
9826
90 235,40
20
27826
255 113,78
15/04/2026
23
13101
123 378,41
32
10601
100 433,87
16/04/2026
27
13751
126 516,35
5
2251
21 099,34
17/04/2026
27
10251
92 889,03
18
11251
102 460,04
20/04/2026
21
11001
99 908,99
16
8001
74 583,96
21/04/2026
31
14251
128 304,18
9
4251
39 049,13
22/04/2026
18
6752
59 455,34
6
752
6 655,46
23/04/2026
74
32250
271 523,07
11
4500
40 177,44
24/04/2026
20
10501
86 286,61
11
6751
56 363,22
27/04/2026
20
7900
64 510,14
12
5064
41 394,81
28/04/2026
47
20152
162 935,17
44
19001
153 894,61
29/04/2026
33
18251
144 993,06
24
10266
81 569,63
30/04/2026
29
16031
128 173,30
39
24235
194 083,57
04/05/2026
17
6230
50 669,09
25
5698
46 934,20
05/05/2026
21
5237
42 558,22
8
4036
33 177,57
06/05/2026
7
2500
20 730,05
14
5751
47 876,27
07/05/2026
16
6799
57 531,64
26
10001
84 805,98
08/05/2026
24
8633
71 211,20
19
10181
85 633,41
11/05/2026
18
4501
38 843,49
20
15462
136 373,14
12/05/2026
28
11412
99 934,20
22
11252
99 490,18
13/05/2026
9
5734
50 144,00
14
7985
70 905,36
14/05/2026
23
9551
85 059,87
23
11256
100 488,62
15/05/2026
37
16326
143 161,71
33
11448
100 732,10
18/05/2026
27
7539
63 792,61
12
6500
55 574,87
19/05/2026
12
6000
50 392,50
15
7661
64 878,40
20/05/2026
11
4501
37 958,51
17
7000
59 512,53
21/05/2026
31
9751
83 008,61
21
8751
74 882,48
22/05/2026
39
14501
124 332,59
1
1
8,74
25/05/2026
13
8751
75 443,60
8
4501
39 166,08
26/05/2026
26
13971
120 203,27
11
6971
60 499,43
27/05/2026
27
12721
107 364,10
24
12441
105 894,56
28/05/2026
20
8251
70 208,58
21
13531
115 811,83
29/05/2026
22
10210
89 995,94
16
7960
70 858,01
01/06/2026
16
10751
92 705,55
8
2251
20 078,83
02/06/2026
19
7730
66 376,74
16
5230
45 366,90
03/06/2026
22
10001
84 786,08
31
15002
127 952,06
04/06/2026
1
1
8,55
45
30000
268 256,40
05/06/2026
56
27966
255 864,29
30
13966
131 723,26
08/06/2026
30
15272
130 761,77
25
15272
131 671,06
09/06/2026
46
28501
243 832,90
13
6751
58 428,49
10/06/2026
31
15250
127 543,22
19
12114
101 593,21
11/06/2026
22
9079
77 802,94
31
18965
164 550,58
12/06/2026
24
12251
110 481,48
42
22001
203 289,02
15/06/2026
20
9001
85 321,92
52
24001
229 736,85
16/06/2026
31
20251
194 852,29
16
7553
75 032,79
17/06/2026
14
9053
84 701,14
20
12251
119 468,08
18/06/2026
4
1751
17 422,45
58
17501
182 626,09
19/06/2026
30
17251
175 765,44
38
26001
275 305,35
22/06/2026
31
13152
141 067,43
33
15402
167 344,27
23/06/2026
24
7751
81 719,10
57
24072
260 350,48
24/06/2026
50
19501
208 246,11
13
4930
54 895,99
25/06/2026
76
33251
320 218,44
3
3501
33 865,28
26/06/2026
21
8001
73 952,60
21
14501
142 513,22
29/06/2026
10
4751
49 870,15
76
18251
192 544,76
30/06/2026
41
19255
204 264,55
39
19255
205 728,89
1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®
Attachment
